Cheil Bio Co

Cheil Bio Co Receivables

Delisted·Feb 25, 2026

The Accounts Receivable of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is 2.47 B KRW. In the previous year, Accounts Receivable was 1.31 B KRW — a change of 88.04% (higher).

Receivables

2.47 BKRW

YoY

88.04%

Last updated:

Accounts Receivable of Cheil Bio Co is 2023 2.47 B KRW. Accounts Receivable of Cheil Bio Co was 2022 1.31 B KRW. It decreases by 88.04% higher compared to the previous year.

The Cheil Bio Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2016
5.86 B KRW
Jan 1, 2017
3.54 B KRW
Jan 1, 2018
2.65 B KRW
Jan 1, 2019
2.82 B KRW
Jan 1, 2020
2.45 B KRW
Jan 1, 2021
1.89 B KRW
Jan 1, 2022
1.31 B KRW
Jan 1, 2023
2.47 B KRW
The Cheil Bio Co Receivables history
YEARReceivablesYoY
2.47 BKRW+88.04%
1.31 BKRW-30.46%
1.89 BKRW-23.06%
2.45 BKRW-13.10%
2.82 BKRW+6.69%
2.65 BKRW-25.14%
3.54 BKRW-39.62%
5.86 BKRW-5.27%
6.18 BKRW-7.86%
6.71 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

Accounts Receivable of Cheil Bio Co is 2.47 B KRW in 2023.

Accounts Receivable of Cheil Bio Co changed from 1.31 B KRW to 2.47 B KRW, representing a 88.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Cheil Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cheil Bio Co

All Key Metrics — Cheil Bio Co